10-Q 1 admt20231231c_10q.htm FORM 10-Q admt20231231c_10q.htm
Q3 2023 --03-31 false 0000849401 3 0.01 0.00 7 5 0 0 0 0 0.01 0.01 00008494012023-04-012023-12-31 thunderdome:item iso4217:USDxbrli:shares 00008494012022-12-31 xbrli:shares 00008494012023-12-31 00008494012022-04-012022-12-31 00008494012022-03-31 00008494012023-03-31 0000849401admt:WarrantOneMember2023-12-31 utr:Y 0000849401admt:WarrantOneMember2023-04-012023-12-31 utr:M 0000849401admt:ConsultingAgreementMember2023-04-11 iso4217:USD xbrli:pure 0000849401admt:ConsultingAgreementMemberus-gaap:MeasurementInputPriceVolatilityMember2023-04-11 0000849401us-gaap:RevolvingCreditFacilityMember2023-03-31 0000849401us-gaap:RevolvingCreditFacilityMember2023-12-31 0000849401us-gaap:RevolvingCreditFacilityMember2023-09-30 0000849401us-gaap:RevolvingCreditFacilityMember2021-09-072021-09-07 0000849401us-gaap:RevolvingCreditFacilityMember2018-06-15 0000849401admt:PPPTermLoanOneMember2023-12-31 0000849401admt:PPPTermLoanOneMember2021-09-072021-09-07 0000849401admt:PPPTermLoanOneMember2021-09-07 0000849401admt:PaycheckProtectionProgramCaresActMemberus-gaap:LoansPayableMember2021-12-212021-12-21 0000849401admt:PaycheckProtectionProgramCaresActMember2021-09-072021-09-07 0000849401admt:PaycheckProtectionProgramCaresActMember2020-05-012021-02-28 0000849401admt:PaycheckProtectionProgramCaresActMember2021-02-012021-02-28 0000849401admt:PaycheckProtectionProgramCaresActMember2020-05-012020-05-30 00008494012022-10-012022-12-31 00008494012023-10-012023-12-31 0000849401admt:EngineeringServicesMemberadmt:QolMember2023-03-31 0000849401admt:EngineeringServicesMemberadmt:QolMember2023-12-31 0000849401admt:EngineeringServicesMemberadmt:QolMember2017-04-012018-03-31 0000849401admt:QolMember2023-12-31 0000849401us-gaap:NonUsMember2022-04-012022-12-31 0000849401us-gaap:NonUsMember2023-04-012023-12-31 0000849401admt:EngineeringMemberus-gaap:NonUsMember2022-04-012022-12-31 0000849401admt:EngineeringMemberus-gaap:NonUsMember2023-04-012023-12-31 0000849401admt:ElectronicsMemberus-gaap:NonUsMember2022-04-012022-12-31 0000849401admt:ElectronicsMemberus-gaap:NonUsMember2023-04-012023-12-31 0000849401admt:ChemicalMemberus-gaap:NonUsMember2022-04-012022-12-31 0000849401admt:ChemicalMemberus-gaap:NonUsMember2023-04-012023-12-31 0000849401country:US2022-04-012022-12-31 0000849401country:US2023-04-012023-12-31 0000849401admt:EngineeringMembercountry:US2022-04-012022-12-31 0000849401admt:EngineeringMembercountry:US2023-04-012023-12-31 0000849401admt:ElectronicsMembercountry:US2022-04-012022-12-31 0000849401admt:ElectronicsMembercountry:US2023-04-012023-12-31 0000849401admt:ChemicalMembercountry:US2022-04-012022-12-31 0000849401admt:ChemicalMembercountry:US2023-04-012023-12-31 0000849401us-gaap:NonUsMember2022-10-012022-12-31 0000849401us-gaap:NonUsMember2023-10-012023-12-31 0000849401admt:EngineeringMemberus-gaap:NonUsMember2022-10-012022-12-31 0000849401admt:EngineeringMemberus-gaap:NonUsMember2023-10-012023-12-31 0000849401admt:ElectronicsMemberus-gaap:NonUsMember2022-10-012022-12-31 0000849401admt:ElectronicsMemberus-gaap:NonUsMember2023-10-012023-12-31 0000849401admt:ChemicalMemberus-gaap:NonUsMember2022-10-012022-12-31 0000849401admt:ChemicalMemberus-gaap:NonUsMember2023-10-012023-12-31 0000849401country:US2022-10-012022-12-31 0000849401country:US2023-10-012023-12-31 0000849401admt:EngineeringMembercountry:US2022-10-012022-12-31 0000849401admt:EngineeringMembercountry:US2023-10-012023-12-31 0000849401admt:ElectronicsMembercountry:US2022-10-012022-12-31 0000849401admt:ElectronicsMembercountry:US2023-10-012023-12-31 0000849401admt:ChemicalMembercountry:US2022-10-012022-12-31 0000849401admt:ChemicalMembercountry:US2023-10-012023-12-31 0000849401us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberadmt:ForeignCustomersMember2022-04-012022-12-31 0000849401us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberadmt:ForeignCustomersMember2022-10-012022-12-31 0000849401us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberadmt:ForeignCustomersMember2023-04-012023-12-31 0000849401us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberadmt:ForeignCustomersMember2023-10-012023-12-31 0000849401admt:AccountsPayableBalanceMemberadmt:VendorConcentrationRiskMemberadmt:ThreeVendorsMember2022-04-012023-03-31 0000849401admt:AccountsPayableBalanceMemberadmt:VendorConcentrationRiskMember2022-04-012023-03-31 0000849401admt:AccountsPayableBalanceMemberadmt:VendorConcentrationRiskMemberadmt:ThreeVendorsMember2023-04-012023-12-31 0000849401us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberadmt:TwoCustomersMember2023-04-012023-12-31 0000849401us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberadmt:FourCustomersMember2023-04-012023-12-31 0000849401us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberadmt:TwoCustomersMember2022-04-012022-12-31 0000849401us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberadmt:TwoCustomersMember2023-04-012023-12-31 0000849401us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberadmt:TwoCustomersMember2022-10-012022-12-31 0000849401us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberadmt:TwoCustomersMember2023-10-012023-12-31 00008494012023-09-30 0000849401admt:SoftwareMember2023-03-31 0000849401admt:SoftwareMember2023-12-31 0000849401admt:SoftwareMember2023-04-012023-12-31 0000849401admt:PatentsAndTrademarksMember2023-03-31 0000849401admt:PatentsAndTrademarksMembersrt:MaximumMember2022-04-012023-03-31 0000849401admt:PatentsAndTrademarksMembersrt:MinimumMember2022-04-012023-03-31 0000849401admt:PatentsAndTrademarksMembersrt:MinimumMember2023-12-31 0000849401admt:PatentsAndTrademarksMember2023-12-31 0000849401admt:PatentsAndTrademarksMembersrt:MinimumMember2023-04-012023-12-31 0000849401srt:MaximumMember2023-09-30 0000849401srt:MinimumMember2023-09-30 0000849401admt:LongTermMember2023-03-31 0000849401admt:CurrentMember2023-03-31 0000849401admt:LongTermMember2023-12-31 0000849401admt:CurrentMember2023-12-31 0000849401srt:MaximumMember2023-12-31 0000849401srt:MinimumMember2023-12-31 0000849401us-gaap:RetainedEarningsMember2023-12-31 0000849401us-gaap:AdditionalPaidInCapitalMember2023-12-31 0000849401us-gaap:CommonStockMember2023-12-31 0000849401us-gaap:RetainedEarningsMember2023-10-012023-12-31 0000849401us-gaap:AdditionalPaidInCapitalMember2023-10-012023-12-31 0000849401us-gaap:RetainedEarningsMember2023-09-30 0000849401us-gaap:AdditionalPaidInCapitalMember2023-09-30 0000849401us-gaap:CommonStockMember2023-09-30 00008494012023-07-012023-09-30 0000849401us-gaap:RetainedEarningsMember2023-07-012023-09-30 0000849401us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-30 00008494012023-06-30 0000849401us-gaap:RetainedEarningsMember2023-06-30 0000849401us-gaap:AdditionalPaidInCapitalMember2023-06-30 0000849401us-gaap:CommonStockMember2023-06-30 00008494012023-04-012023-06-30 0000849401us-gaap:RetainedEarningsMember2023-04-012023-06-30 0000849401us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-30 0000849401us-gaap:RetainedEarningsMember2023-03-31 0000849401us-gaap:AdditionalPaidInCapitalMember2023-03-31 0000849401us-gaap:CommonStockMember2023-03-31 0000849401us-gaap:RetainedEarningsMember2022-12-31 0000849401us-gaap:AdditionalPaidInCapitalMember2022-12-31 0000849401us-gaap:CommonStockMember2022-12-31 0000849401us-gaap:RetainedEarningsMember2022-10-012022-12-31 00008494012022-09-30 0000849401us-gaap:RetainedEarningsMember2022-09-30 0000849401us-gaap:AdditionalPaidInCapitalMember2022-09-30 0000849401us-gaap:CommonStockMember2022-09-30 00008494012022-07-012022-09-30 0000849401us-gaap:RetainedEarningsMember2022-07-012022-09-30 00008494012022-06-30 0000849401us-gaap:RetainedEarningsMember2022-06-30 0000849401us-gaap:AdditionalPaidInCapitalMember2022-06-30 0000849401us-gaap:CommonStockMember2022-06-30 00008494012022-04-012022-06-30 0000849401us-gaap:RetainedEarningsMember2022-04-012022-06-30 0000849401us-gaap:AdditionalPaidInCapitalMember2022-04-012022-06-30 0000849401us-gaap:RetainedEarningsMember2022-03-31 0000849401us-gaap:AdditionalPaidInCapitalMember2022-03-31 0000849401us-gaap:CommonStockMember2022-03-31 0000849401us-gaap:RelatedPartyMember2023-03-31 0000849401us-gaap:RelatedPartyMember2023-12-31 00008494012024-02-14
 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 10-Q

 

(Mark One)

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended December 31, 2023

 

OR

 

TRANSACTION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from           to        

 

COMMISSION FILE NO. 0-17629

 

ADM TRONICS UNLIMITED, INC.
(Exact name of registrant as specified in its charter)

 

Delaware

(State or Other Jurisdiction

of Incorporation or or organization)

22-1896032

(I.R.S. Employer

Identification Number)

 

224-S Pegasus Ave.NorthvaleNew Jersey 07647
(Address of Principal Executive Offices)

 

Registrant's Telephone Number, including area code: (201767-6040

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading Symbol(s)

Name of each exchange on which

registered

None

N/A

N/A

 

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days:  Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐

Accelerated filer  ☐

   

Non-accelerated filer ☐

Smaller reporting company 

   
 

Emerging growth company 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes  No ☒

 

State the number of shares outstanding of each of the Issuer's classes of common equity, as of the latest practicable date:

 

The Company has 67,588,504 shares outstanding as of February 14, 2024. 

 

 

 

 

ADM TRONICS UNLIMITED, INC. AND SUBSIDIARY

 

INDEX

 

 

Page

Number

Part I - Financial Information

 
     

Item 1.

Condensed Consolidated Financial Statements (unaudited):

 
     
 

Condensed Consolidated Balance Sheets –December 31, 2023 (unaudited) and March 31, 2023

3

     
 

Condensed Consolidated Statements of Operations for the three and nine months ended December 31, 2023 and 2022 (unaudited)

4

     
 

Condensed Consolidated Statement of Stockholders’ Equity for the three and nine months ended December 31, 2023 and 2022 (unaudited)

5

     
 

Condensed Consolidated Statements of Cash Flows for the nine months ended December 31, 2023 and 2022 (unaudited)

6

     
 

Notes to Condensed Consolidated Financial Statements

7

     

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

15

     

Item 3.

Quantitative and Qualitative Disclosures about Market Risk

19

     

Item 4.

Controls and Procedures

19

     

Part II - Other Information

 
     

Item 1.

Legal Proceedings

20

     

Item 1A.

Risk Factors

20

     

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

20

     

Item 3.

Defaults Upon Senior Securities

20

     

Item 4.

Mine Safety Disclosures

20

     

Item 5.

Other Information

20

     

Item 6.

Exhibits

20

 

 

 

 

PART I. FINANCIAL INFORMATION

ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

ADM TRONICS UNLIMITED, INC. AND SUBSIDIARY

CONDENSED CONSOLIDATED BALANCE SHEETS 

 

   

December 31,

   

March 31,

 
   

2023

   

2023

 
   

(Unaudited)

         

ASSETS

               
                 

Current assets:

               

Cash and cash equivalents

  $ 661,985     $ 1,003,730  

Accounts receivable, net of allowance for credit losses of $429,972 and $694,871 at December 31, 2023 and March 31, 2023, respectively

    780,882       497,793  

Inventories

    487,431       443,465  

Prepaid expenses and other current assets

    8,082       41,251  
                 

Total current assets

    1,938,380       1,986,239  
                 

Other Assets:

               

Long-term inventory

  $ 141,696     $ 228,451  

Operating lease right-of-use asset

    420,421       481,535  

Loan receivable,

    -       209,809  

Due from affiliate

    -       80,090  

Intangible assets, net of accumulated amortization of $26,001 and $22,631 at December 31, 2023 and March 31, 2023, respectively

    24,308       13,163  

Other assets

    90,538       90,538  

Deferred tax asset

    -       -  

Total other assets

    676,963       1,103,586  
                 

Total assets

  $ 2,615,343     $ 3,089,825  
                 

LIABILITIES AND STOCKHOLDERS' EQUITY

               
                 

Current liabilities:

               

Accounts payable

  $ 293,497     $ 322,639  

Bank overdraft

    145,115       134,837  

Accrued expenses and other current liabilities

    100,531       75,659  

PPP loan

    7,621       11,656  

Line of credit

    298,378       112,809  

Operating lease liability

    87,727       82,917  

Customer deposits

    235,348       359,723  

Due to stockholder

    -       13,626  

Total current liabilities

    1,168,217       1,113,866  
                 

Long-term liabilities

               

PPP loan less current portion

    -       -  

Operating lease liability less current portion

    343,926       410,474  

Total long-term liabilities

    343,926       410,474  
                 
                 

Total liabilities

    1,512,143       1,524,340  
                 

Stockholders' equity:

               

Preferred stock, $.01 par value; 5,000,000 shares authorized, no shares issued and outstanding

    -       -  

Common stock, $0.0005 par value; 150,000,000 shares authorized, 67,588,492 shares issued and outstanding

    33,794       33,794  

Additional paid-in capital

    33,602,612       33,599,516  

Accumulated deficit

    (32,533,206 )     (32,067,825 )

Total stockholders' equity

    1,103,200       1,565,485  
                 

Total liabilities and stockholders' equity

  $ 2,615,343     $ 3,089,825  

 

See accompanying notes to the unaudited condensed consolidated financial statements

 

3

 

 

ADM TRONICS UNLIMITED, INC. AND SUBSIDIARY

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

FOR THE THREE AND NINE MONTHS ENDED DECEMBER 31, 2023 AND 2022 

 

   

Three months ended

   

Nine months ended

 
   

December 31,

   

December 31,

 
   

2023

   

2022

   

2023

   

2022

 
                                 

Net revenues

  $ 696,496     $ 983,162     $ 2,213,317     $ 3,044,838  
                                 

Cost of sales

    375,075       507,684       1,360,602       1,628,268  
                                 

Gross Profit

    321,421       475,478       852,715       1,416,570  
                                 

Operating expenses:

                               

Research and development

    177,502       140,192       439,832       399,894  

Selling, general and administrative

    249,306       242,533       883,716       855,656  
                                 

Total operating expenses

    426,808       382,725       1,323,548       1,255,550  
                                 

Income (loss) from operations

    (105,387 )     92,753       (470,833 )     161,020  
                                 

Other income (expense):

                               

Interest income

    5,663       3,676       20,256       4,670  

Interest and finance expenses

    (5,291 )     (2,658 )     (14,804 )     (10,542 )

Total other income (expense)

    372       1,018       5,452       (5,872 )
                                 

Income (loss) before provision for income taxes

    (105,015 )     93,771       (465,381 )     155,148  
                                 

Total provision (benefit) for income taxes

    -       -       -       -  
                                 

Net income (loss)

  $ (105,015 )   $ 93,771     $ (465,381 )   $ 155,148  
                                 

Basic and diluted per common share:

  $ (0.00 )   $ 0.00     $ (0.01 )   $ 0.00  
                                 

Weighted average shares of common stock outstanding - basic and diluted

    67,588,492       67,588,492       67,588,492       67,588,492  

 

See accompanying notes to the unaudited condensed consolidated financial statements

 

4

 

 

ADM TRONICS UNLIMITED, INC. AND SUBSIDIARY

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY (UNAUDITED)

FOR THE NINE MONTHS ENDED December 31, 2023 AND 2022 

 

   

Common Stock

   

Common Stock

   

Additional Paid-in

   

Accumulated

         
   

Shares

   

Amount

   

Capital

   

Deficit

   

Total

 
                                         

Balance at April 1, 2022

    67,588,492     $ 33,794     $ 33,311,672     $ (31,971,503 )   $ 1,373,963  
                                         

Stock based compensation

                    287,844               287,844  
                                         

Net (loss)

                          $ (38,666 )     (38,666 )
                                         

Balance at June 30, 2022

    67,588,492     $ 33,794     $ 33,599,516     $ (32,010,169 )   $ 1,623,141  
                                         

Net income

                          $ 100,043       100,043  
                                         

Balance at September 30, 2022

    67,588,492     $ 33,794     $ 33,599,516     $ (31,910,126 )   $ 1,723,184  
                                         

Net income

                          $ 93,771       93,771  
                                         

Balance at December 31, 2022

    67,588,492     $ 33,794     $ 33,599,516     $ (31,816,355 )   $ 1,816,955  
                                         
                                         
                                         

Balance at April 1, 2023

    67,588,492     $ 33,794     $ 33,599,516     $ (32,067,825 )   $ 1,565,485  
                                         

Stock based compensation

                    1,032               1,032  
                                         

Net income (loss)

                            (132,261 )     (132,261 )
                                         

Balance at June 30, 2023

    67,588,492     $ 33,794     $ 33,600,548     $ (32,200,086 )   $ 1,434,256  
                                         

Stock based compensation

                    1,032               1,032  
                                         

Net (loss)

                            (228,105 )     (228,105 )
                                         

Balance at September 30, 2023

    67,588,492     $ 33,794     $ 33,601,580     $ (32,428,191 )   $ 1,207,183  
                                         

Stock based compensation

                    1,032               1,032  
                                         

Net (loss)

                            (105,015 )     (105,015 )
                                         

Balance at December 31, 2023

    67,588,492     $ 33,794     $ 33,602,612     $ (32,533,206 )   $ 1,103,200  

 

See accompanying notes to the unaudited condensed consolidated financial statements

 

5

 

 

ADM TRONICS UNLIMITED, INC. AND SUBSIDIARY

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

FOR THE NINE MONTHS ENDED DECEMBER 31, 2023 AND 2022

 

   

2023

   

2022

 

Cash flows from operating activities:

               

Net income (loss)

  $ (465,381 )   $ 155,148  

Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:

               

Amortization

    3,370       2,160  

Write-off of inventories

    33,945       54,692  
Change in allowance for credit losses     (305,090 )        

Loan impairment

    209,809          

Non-cash interest expense

    17,168       20,320  

Amortization of right-to-use asset

    61,114       61,577  

Stock based compensation

    3,096       33,310  

Changes in operating assets and liabilities balances:

               

Accounts receivable

    102,091       171,436  

Inventories

    8,844       (189,971 )

Prepaid expenses and other current assets

    33,169       47,622  

Loan receivable

    -       (72,881 )

Accounts payable

    (29,142 )     (66,215 )

Bank overdraft

    10,278       -  

Customer deposits

    (124,375 )     98,565  

Accrued expenses and other current liabilities

    24,873       (24,335 )

Payments of operating lease liability

    (78,906 )     (76,406 )

Net cash provided by (used in) operating activities

    (495,137 )     215,022  
                 

Cash flows from investing activities:

               

Purchase of software

    (14,515 )     -  

Net cash (used in) investing activities

    (14,515 )     -  
                 

Cash flows provided (used) in financing activities:

               

Due to shareholder

    (13,626 )     (29,104 )

Proceeds from line of credit

    233,328       85,067  

Repayments of line of credit

    (47,760 )     (307,764 )

Proceeds (payments) from/to PPP loan

    (4,035 )     (4,034 )
                 

Net cash provided by (used in) financing activities

    167,907       (255,835 )
                 

Net (decrease) in cash and cash equivalents

    (341,745 )     (40,813 )
                 

Cash and cash equivalents - beginning of period

    1,003,730       1,038,498  
                 

Cash and cash equivalents - end of period

  $ 661,985     $ 997,685  
                 
                 

Cash paid for:

               

Interest

  $ 20,256     $ 7,884  

Non-cash activities:

               

Reclass of Warrant Liability to Additional Paid in Capital

  $ -     $ (182,161 )

Initial recognition of prepaid warrant expense

  $ -     $ (105,683 )

 

See accompanying notes to the unaudited condensed consolidated financial statements

 

6

 

ADM TRONICS UNLIMITED, INC. AND SUBSIDIARY

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

FOR THE THREE AND NINE MONTHS ENDED December 31, 2023 AND 2022 

 

 

NOTE 1  - NATURE OF BUSINESS

 

ADM Tronics Unlimited, Inc. (“we”, “us”, the “Company” or “ADM”), was incorporated under the laws of the state of Delaware on November 24, 1969. We are a manufacturing and engineering concern whose principal lines of business are the design, manufacture, and sale of electronics of our own products or on a contract manufacturing basis; the production and sale of chemical and antistatic products; and, research, development and engineering services.

 

Electronic equipment is manufactured in accordance with customer specifications on a contract basis. Our electronic device product line consists principally of proprietary devices used in diagnostics and therapeutics of humans and animals and electronic controllers for spas and hot tubs. These products are sold to customers located principally in the United States. We are registered with the FDA as a contract manufacturing facility and we manufacture medical devices for customers in accordance with their designs and specifications. Our chemical product line is principally comprised of water-based chemical products used in the food packaging and converting industries, and anti-static conductive paints, coatings and other products. These products are sold to customers located in the United States, Australia, Asia and Europe. We also provide research, development, regulatory, and engineering services to customers. Our Sonotron Medical Systems, Inc. subsidiary (“Sonotron”) is involved in medical electronic therapeutic technology.

 

 

NOTE 2  - SIGNIFICANT ACCOUNTING POLICIES

 

BASIS OF PRESENTATION

 

The accompanying unaudited condensed consolidated financial statements have been prepared by ADM pursuant to accounting principles generally accepted in the United States of America (“GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”) including Form 10-Q and Regulation S-X. The information furnished herein reflects all adjustments (consisting of normal recurring accruals and adjustments) which are, in the opinion of management, necessary to fairly present the condensed financial position and operating results for the respective periods. Certain information and footnote disclosures normally present in annual financial statements prepared in accordance with GAAP have been omitted pursuant to such rules and regulations. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and explanatory notes for the year ended March 31, 2023 as disclosed in our annual report on Form 10-K for that year. Unaudited interim results are not necessarily indicative of the results for the full fiscal year ending March 31, 2024. The consolidated balance sheet as of March 31, 2023 was derived from the audited consolidated financial statements as of and for the year then ended.

 

PRINCIPLES OF CONSOLIDATION

 

The condensed consolidated financial statements include the accounts of ADM Tronics Unlimited, Inc. and its wholly owned subsidiary, Sonotron (the “Company”). All significant intercompany balances and transactions have been eliminated in consolidation.

 

7

 

USE OF ESTIMATES

 

These unaudited condensed consolidated financial statements have been prepared in accordance with GAAP and, accordingly, requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures of contingent assets and liabilities. Significant estimates made by management include expected economic life and value of our deferred tax assets and related valuation allowance, write down of inventory, impairment of long-lived assets, allowance for doubtful accounts, and warranty reserves. Actual results could differ from those estimates.

 

FAIR VALUE OF FINANCIAL INSTRUMENTS

 

For certain of our financial instruments, including accounts receivable, accounts payable, and accrued expenses, the carrying amounts approximate fair value due to their relatively short maturities.

 

CASH AND CASH EQUIVALENTS

 

Cash equivalents are comprised of highly liquid investments with original maturities of three months or less when purchased. We maintain our cash in bank deposit accounts, which at times, may exceed federally insured limits. We have not experienced any losses to date as a result of this policy. Cash and cash equivalents held in these accounts are currently insured by the Federal Deposit Insurance Corporation (“FDIC”) up to a maximum of $250,000. At December 31, 2023 and March 31, 2023, approximately $412,000 and $754,000, respectively, exceeded the FDIC limit.

 

ACCOUNTS RECEIVABLE AND ALLOWANCE FOR CREDIT LOSSES

 

Accounts receivable are stated at the amount management expects to collect from outstanding balances. The carrying amounts of accounts receivable is reduced by a valuation allowance that reflects management's best estimate of the amounts that will not be collected. Management individually reviews all accounts receivable balances that exceed the due date and estimates the portion, if any, of the balance that will be collected. Management provides for probable uncollectible amounts through a charge to expenses and a credit to a valuation allowance, based on its assessment of the current status of individual accounts. Balances that are still outstanding after management has used reasonable collection efforts are written off through a charge to the valuation allowance and a credit to accounts receivable.

 

REVENUE RECOGNITION

 

ELECTRONICS:

 

We recognize revenue from the sale of our electronic products when they are shipped to the purchaser. We offer a limited 90-day warranty on our electronics products and contract manufacturing, and a limited 5-year warranty on our electronic controllers for spas and hot tubs. Historically, the amount of warranty expense included in sales of our electronic products have been de minimis. We have no other post shipment obligations. For contract manufacturing, revenues are recognized after shipments of the completed products.

 

Amounts received from customers in advance of our satisfaction of applicable performance obligations are recorded as customer deposits. Such amounts are recognized as revenues when the related performance obligations are satisfied. Customer deposits of approximately $128,000 and $212,000 as of March 31, 2023 were recognized as revenues during the three and nine months ended December 31, 2023, respectively.

 

Amounts received from customers in advance of our satisfaction of applicable performance obligations are recorded as customer deposits. Such amounts are recognized as revenues when the related performance obligations are satisfied. Customer deposits of approximately $120,000 and $209,000 as of March 31, 2022 were recognized as revenues during the three and nine months ended December 31, 2022, respectively.

 

CHEMICAL PRODUCTS:

 

Revenues are recognized when products are shipped to end users. Shipments to distributors are recognized as revenue when no right of return exists.

 

ENGINEERING SERVICES:

 

We provide certain engineering services, including research, development, quality control, and quality assurance services along with regulatory compliance services. We recognize revenue from engineering services over time as the applicable performance obligations are satisfied.

 

All revenue is recognized net of discounts.

 

8

 

INVENTORIES

 

Inventories are stated at the lower of cost (first-in, first-out method) and net realizable value. Inventories that are expected to be sold within one operating cycle (1 year) are classified as a current asset. Inventories that are not expected to be sold within 1 year, based on historical trends, are classified as Inventories - long term portion. Obsolete inventory is written off based on prior and expected future usage.

 

Long-Term Inventory: Due to recent shortages of materials relating to supply chain and COVID issues, when an item the Company believes will be used in the future, even beyond the current fiscal year, becomes available, it will purchase as many items as management deems necessary to fulfill future orders.

 

PROPERTY AND EQUIPMENT

 

We record our property and equipment at historical cost. We expense maintenance and repairs as incurred. Depreciation is provided for by the straight-line method over five to seven years, the estimated useful lives of the property and equipment. As of December 31, 2023 and March 31, 2023, all fixed assets were fully depreciated.

 

ADVERTISING COSTS

 

Advertising costs are expensed as incurred and amounted to $5,908 and $17,041 for the three and nine months ended December 31, 2023 and $6,184 and $21,216 for the three and nine months ended December 31, 2022 , respectively.

 

NET EARNINGS PER SHARE

 

We compute basic earnings per share by dividing net income/loss by the weighted average number of common shares outstanding. Diluted earnings per share is computed similar to basic earnings per share, except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential shares had been issued and if the additional shares were dilutive. Common equivalent shares are excluded from the computation of net earnings per share if their effect is anti-dilutive.

 

There were 200,000 and -0- anti-dilutive instruments in force during the periods ended December 31, 2023 and 2022, respectively.

 

Per share basic and diluted (loss) amounted to $(0.00) and $(0.01) and $0.00 and $0.00 for the three and nine months ended December 31, 2023 and 2022, respectively.

 

LEASES

 

In February 2016, the Financial Accounting Standards Board (“FASB”) issued authoritative guidance which changed financial reporting as it relates to leasing transactions. Under the new guidance, lessees are required to recognize a lease liability, measured on a discounted basis; and a right-of-use asset, for the lease term. The Company adopted this guidance as of April 1, 2019, using the modified retrospective approach which allowed it to initially apply the guidance as of the adoption date. The Company elected the package of practical expedients available under the new standard, which allowed the Company to forgo a reassessment of (1) whether any expired or existing contracts are or contain leases, (2) the lease classification for any expired or existing leases, and (3) the initial direct costs for any existing leases.

 

The Company made a policy election to recognize short-term lease payments as an expense on a straight-line basis over the lease term. The Company defines a short-term lease as a lease that, at the commencement date, has a lease term of twelve months or less and does not contain an option to purchase the underlying asset that the lease is reasonably certain to exercise. Related variable lease payments are recognized in the period in which the obligation is incurred.

 

The Company's lease agreement contains related non-lease components (e.g. taxes, etc.). The Company separates lease components and non-lease components for all underlying asset classes.

 

RECLASSIFICATION

 

Certain amounts in the prior periods presented have been reclassified to conform to the current period financial statement presentation. These reclassifications have no effect on previously reported net loss.

 

NEW ACCOUNTING STANDARDS

 

In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The FASB subsequently issued amendments to ASU 2016-13, which have the same effective date and transition date of April 1, 2023. These standards replace the existing incurred loss impairment model with an expected credit loss model and requires a financial asset measure at amortized cost to be presented at the net amount expected to be collected. The Company determined that this change does not have a material impact to the financial statements or financial statement disclosures.

 

9

 

 

 

NOTE 3 - INVENTORIES     

 

Inventories at December 31, 2023 consisted of the following:

 

   

Current

   

Long Term

   

Total

 

Raw materials

  $ 426,480     $ 135,698     $ 562,178  

Finished goods

    60,951       5,998       66,949  

Totals

  $ 487,431     $ 141,696     $ 629,127  

              

Inventories at March 31, 2023 consisted of the following:   

     

   

Current

   

Long Term

   

Total

 

Raw materials

  $ 390,792     $ 201,317     $ 592,109  

Finished goods

    52,673       27,134       79,807  

Totals

  $ 443,465     $ 228,451     $ 671,916  

 

 

 

NOTE 4 - INTANGIBLE ASSETS

 

Intangible assets are being amortized using the straight-line method over periods ranging from 10-15 years with a weighted average remaining life of approximately 6 years.

 

   

December 31, 2023

   

March 31, 2023

 
   

Cost

   

Weighted Average Amortization Period

(Years)

   

Accumulated Amortization

   

Net

Carrying

Amount

   

Cost

   

Weighted Average Amortization Period

(Years)

   

Accumulated Amortization

   

Net Carrying Amount

 

Patents & Trademarks

  $ 35,794       10 - 15     $ (24,791 )   $ 11,003     $ 35,794       10 - 15     $ (22,631 )   $ 13,163  

Software

  $ 14,515         3       $ (1,210 )   $ 13,305     $ -                 $ -     $ -  
                                                                         
    $ 50,309                 $ (26,001 )   $ 24,308     $ 35,794                 $ (22,631 )   $ 13,163  

 

10

 

Estimated aggregate future amortization expense related to intangible assets is as follows:

 

For the fiscal years ended March 31,

       

2024

  $ 3,862  

2025

    7,115  

2026

    6,716  

2027

    2,931  

2028

    1,726  

Thereafter

    1,958  
    $ 24,308  

 

 

 

NOTE 5 – CONCENTRATIONS

 

During the three months ended December 31, 2023, two customers accounted for 53% of our net revenue. During the three months ended December 31, 2022, two customers accounted for 50% of our net revenue.

 

During the nine months ended December 31, 2023, two customers accounted for 44% of our net revenue. During the nine months ended December 31, 2022, two customers accounted for 45% of our net revenue.

 

As of December 31, 2023, four customers represented 91% of our gross accounts receivable. As of March 31, 2023, two customers accounted for 75% of our gross accounts receivable.

 

As of December 31, 2023, three vendors accounted for 36% of our accounts payable balance. As of March 31, 2023 three vendors accounted for 45% of our accounts payable.

 

The Company’s customer base is comprised of foreign and domestic entities with diverse demographics. Net revenues from foreign customers for the three and nine months ended December 31, 2023 were $40,029 or 6% and $238,170 or 11%, respectively.

 

Net revenues from foreign customers for the three and nine months ended December 31, 2022 were $86,296 or 8% and $237,852 or 8%, respectively.

 

 

 

NOTE 6 - DISAGGREGATED REVENUES AND SEGMENT INFORMATION

 

The following tables show the Company's revenues disaggregated by reportable segment and by product and service type:

 

   

Three months Ended December 31,

 
   

2023

   

2022

 

Net Revenue in the US

               

Chemical

  $ 175,402     $ 245,582  

Electronics

    423,593       485,454  

Engineering

    57,472       165,830  
      656,467       896,866  
                 

Net Revenue outside the US

               

Chemical

    40,029       86,296  

Electronics

    -       -  

Engineering

    -       -  
      40,029       86,296  
                 

Total Revenues

  $ 696,496     $ 983,162  

 

11

 

   

Nine Months Ended December 31,

 
   

2023

   

2022

 

Net Revenue in the US

               

Chemical

  $ 598,176     $ 811,596  

Electronics

    1,082,634       1,584,003  

Engineering

    294,337       411,387  
      1,975,147       2,806,986  
                 

Net Revenue outside the US

               

Chemical

    238,170       237,852  

Electronics

    -       -  

Engineering

    -       -  
      238,170       237,852  
                 

Total Revenues

  $ 2,213,317     $ 3,044,838  

 

12

 

 

NOTE 7 – DUE FROM AFFILIATE 

 

The Company has a $75,000 investment for 23.2% of Qol Devices Inc. (Qol). It was determined that the Company does not hold a significant influence which results in us carrying this asset at cost and reported as a component of other assets in the accompanying consolidated balance sheets.

 

The Company provided $330,090 in engineering services to Qol during the year March 31, 2018. This amount is shown net of a $330,090 and $250,000 allowance for credit losses on the consolidated balance sheets as of December 31, 2023 and March 31, 2023.

 

 

 

NOTE 8 – LEASES

 

We lease our office and manufacturing facility under a non-cancelable operating lease, which expires on June 30, 2028. The following is a maturity analysis of the annual undiscounted cash flows of the operating lease liabilities as of December 31, 2022:

 

 

 

For the fiscal year ended:

Amount

 

FY 2024

March 31, 2024

  $ 26,718  

FY 2025

March 31, 2025

    106,872  

FY 2026

March 31, 2026

    106,872  

FY 2027

March 31, 2027

    106,872  

FY 2028

March 31, 2028

    106,872  

FY 2029

March 31, 2029

ends June 30, 2028

    26,718  
          480,924  
 

Less: Amount attributable to imputed interest

    (49,271 )
        $ 431,653  
             
             
 

Weighted average remaining lease term (in years)

    2.7  

 

Rent and real estate tax expense for all facilities for the three and nine months ended December 31, 2023 was approximately was approximately $35,000 and $104,000, respectively.

 

Rent and real estate tax expense for all facilities for the three and nine months ended December 31, 2022 was approximately was approximately $34,000 and $102,000, respectively.

 

These are reported as a component of cost of sales and selling, general and administrative expenses in the accompanying consolidated statements of operations.

 

 

 

NOTE 9 – PAYCHECK PROTECTION PROGRAM (PPP) LOAN

 

In May 2020, the Company obtained funding through the Small Business Administration (“SBA”) Paycheck Protection Program (“PPP”) of $381,000. In February 2021, a second PPP loan was obtained in the amount of $332,542, for a total of $713,542. The loans will be fully forgiven if the funds are used for payroll costs, interest on mortgages, rent, and utilities, with at least 60% being used for payroll. The Company did use the funds for these expenses during the year ended March 31, 2021. The Company applied for loan forgiveness of both PPP loans. On September 7, 2021, the Company received approval from the SBA for $361,275 of PPP loan forgiveness. On December 21, 2021, the Company received approval from the Bank for $332,542. This amount was recorded as Forgiveness of Paycheck Protection loan in the accompanying condensed Consolidated Statements of Operations during the fiscal year ended March 31, 2022.

 

The unforgiven portion of the first PPP loan is $19,725, which was converted to a term loan payable in equal installments of principal plus interest at 1% with a maturity date of May 15, 2025. No collateral or personal guarantees is required for the loan. At December 31, 2023, the outstanding balance is $7,621.

 

13

 

 

NOTE 10 – LINE OF CREDIT

 

On June 15, 2018, the Company obtained an unsecured revolving line of credit, with a limit of $400,000. The line expires May 15, 2024, renewing automatically every year. The Company is required to make monthly interest payments, at a rate of 8.87% as of June 30, 2023. Any unpaid principal will be due upon maturity. At December 31, 2023 and March 31, 2023, the outstanding balance was $298,378 and $112,809, respectively.

 

 

 

NOTE 11  – WARRANTS

 

On April 11, 2023, warrants to purchase Company stock were issued to two outside consultants. Each consultant was granted 100,000 warrants with a strike price of $0.20. The Warrants vested and were exercisable immediately. The warrants were valued using a Black Scholes model effective April 11, 2023, cumulative volatility was computed at 123.52% and the total valuation was $8,256 which will be amortized over the 24-month life.

 

       

Outstanding and exercisable

 

Range of Exercise prices

   

Number

outstanding

   

Weighted average

remaining life in years

   

Weighted Average

Exercise Price

   

Exercisable

 
                                     
$ 0.20       200,000       1.28     $ 0.20       200,000  

 

   

2023

   

2022

 
   

# of Shares

   

Weighted Average

Exercise Price

   

# of Shares

   

Weighted Average

Exercise Price

 

Outstanding, beginning of year

    -       -       -       -  
                                 

Issued

    200,000     $ 0.20       -       -  
                                 

Exercised

    -       -       -       -  
                                 

Expired

    -       -       -       -  
                                 

Cancelled

    -       -       -       -  
                                 

Outstanding, end of period

    200,000     $ 0.20       -       -  
                                 

Exercisable, end of period

    200,000     $ 0.20       -       -  

 

 

 

NOTE 12 – LEGAL PROCEEDINGS

 

We are involved, from time to time, in litigation and proceedings arising out of the ordinary course of business. There are no pending material legal proceedings or environmental investigations to which we are a party or to which our property is subject.

 

14

 

 

NOTE 13 – CONTRACTURAL OBLIGATIONS AND OTHER COMMITMENTS

 

Legal Contingencies

We are involved, from time to time, in litigation and proceedings arising out of the ordinary course of business. There are no pending material legal proceedings or environmental investigations to which we are a party or to which our property is subject.

 

Product Liability

As of December 31, 2023 and March 31, 2023, there were no claims against us for product liability.

 

COVID-19 Pandemic

 

The Company had reduced revenues in the electronic and chemical segments as a result of the Covid pandemic. In the electronic segment certain orders of medical devices manufactured by the Company were reduced or delayed due to the cessation of elective surgeries during the pandemic and generally reduced activities by customers. In the chemical segment certain of the Company’s water-based industrial coatings and adhesives orders were reduced due to some customers having shutdowns or reduced activities during the pandemic. We intend to continue to evaluate and may, in certain circumstances, take preemptive actions to preserve liquidity during the COVID-19 pandemic. As the circumstances around the COVID-19 pandemic remain uncertain, we continue to actively monitor the pandemic's impact on us, including our financial position, liquidity, results of operations, and cash flows.

 

 

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

The following discussion of our operations and financial condition should be read in conjunction with the condensed consolidated financial statements and notes thereto included elsewhere in this Quarterly Report on Form 10-Q. 

 

FORWARD-LOOKING STATEMENTS

 

This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of the "safe harbor" provisions under section 21E of the Securities and Exchange Act of 1934 and the Private Securities Litigation Act of 1995. We use forward-looking statements in our description of our plans and objectives for future operations and assumptions underlying these plans and objectives. Forward-looking terminology includes the words "may", "expects", "believes", "anticipates", "intends", "forecasts", "projects", or similar terms, variations of such terms or the negative of such terms. These forward-looking statements are based on management's current expectations and are subject to factors and uncertainties which could cause actual results to differ materially from those described in such forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained in this Form 10-Q to reflect any change in our expectations or any changes in events, conditions or circumstances on which any forward-looking statement is based. Factors which could cause such results to differ materially from those described in the forward-looking statements include those set forth under "Item. 1 Description of Business – Risk Factors" and elsewhere in or incorporated by reference into our Annual Report on Form 10-K for the year ended March 31, 2023.

 

BUSINESS OVERVIEW

 

The Company is a technology-based developer and manufacturer of diversified lines of products and derives revenue from the production and sale of electronics for medical devices and other applications; environmentally safe chemical products for industrial, medical and cosmetic uses; and, research, development, regulatory and engineering services. The Company has increased internal research and development by utilizing their engineering resources to advance their own proprietary medical device technologies.

 

The Company is a corporation that was organized under the laws of the State of Delaware on November 24, 1969. Our operations are conducted through ADM and its subsidiary Sonotron.  

 

RESULTS OF OPERATIONS FOR THE THREE AND NINE MONTHS ENDED DECEMBER 31, 2023 AS COMPARED TO DECEMBER 31, 2022.  

 

 

For the three months ended December 31, 2023

                         
   

Chemical

   

Electronics

   

Engineering

   

Total

 

Revenue

  $ 215,431     $ 423,593     $ 57,472     $ 696,496  

Cost of Sales

    148,519       215,508       11,048       375,075  

Gross Profit

    66,912       208,085       46,424       321,421  

Gross Profit Percentage

    31 %     49 %     81 %     46 %
                                 

Operating Expenses

    135,290       245,006       46,512       426,808  

Operating Income (Loss)

    (68,378 )     (36,921 )     (88 )     (105,387 )

Other income (expenses)

    (61 )     436       (3 )     372  
                                 

Income (loss) before benefit from income taxes

  $ (68,439 )   $ (36,485 )   $ (91 )   $ (105,015 )

 

15

 

For the three months ended December 31, 2022

                         
   

Chemical

   

Electronics

   

Engineering

   

Total

 

Revenue

  $ 331,878     $ 485,454     $ 165,830     $ 983,162  

Cost of Sales

    187,341       277,133       43,210       507,684  

Gross Profit

    144,537       208,321       122,620       475,478  

Gross Profit Percentage

    44 %     43 %     74 %     48 %
                                 

Operating Expenses

    121,400       190,287       71,038       382,725  

Operating Income (Loss)

    23,137       18,034       51,582       92,753  

Other income (expenses)

    415       598       5       1,018  
                                 

Income (loss) before benefit from income taxes

  $ 23,552     $ 18,632     $ 51,587     $ 93,771  

 

Variance

                               
   

Chemical

   

Electronics

   

Engineering

   

Total

 

Revenue

  $ (116,447 )   $ (61,861 )   $ (108,358 )   $ (286,666 )

Cost of Sales

    (38,822 )     (61,625 )     (32,162 )     (132,609 )

Gross Profit

    (77,625 )     (236 )     (76,196 )     (154,057 )

Gross Profit Percentage

    -12 %     6 %     7 %     -2 %
                                 

Operating Expenses

    13,890       54,719       (24,526 )     44,083  

Operating Income (Loss)

    (91,515 )     (54,955 )     (51,670 )     (198,140 )

Other income (expenses)

    (476 )     (162 )     (8 )     (646 )
                                 

Income (loss) before benefit from income taxes

  $ (91,991 )   $ (55,117 )   $ (51,678 )   $ (198,786 )

 

 

For the nine months ended December 31, 2023

                         
   

Chemical

   

Electronics

   

Engineering

   

Total

 

Revenue

  $ 836,346     $ 1,082,634     $ 294,337     $ 2,213,317  

Cost of Sales

    597,128       646,795       116,679       1,360,602  

Gross Profit

    239,218       435,839       177,658       852,715  

Gross Profit Percentage

    29 %     40 %     60 %     39 %
                                 

Operating Expenses

    502,951       648,539       172,058       1,323,548  

Operating Income (Loss)

    (263,733 )     (212,700 )     5,600       (470,833 )

Other income (expenses)

    2,072       2,672       708       5,452  
                                 

Income before provision for income taxes

  $ (261,661 )   $ (210,028 )   $ 6,308     $ (465,381 )

 

For the nine months ended December 31, 2022

                         
   

Chemical

   

Electronics

   

Engineering

   

Total

 

Revenue

  $ 1,049,448     $ 1,584,003     $ 411,387     $ 3,044,838  

Cost of Sales

    587,012       936,513       104,743       1,628,268  

Gross Profit

    462,436       647,490       306,644       1,416,570  

Gross Profit Percentage

    44 %     41 %     75 %     47 %
                                 

Operating Expenses

    426,888       652,885       175,777       1,255,550  

Operating Income (Loss)

    35,548       (5,395 )     130,867       161,020  

Other income (expenses)

    (1,996 )     (3,054 )     (822 )     (5,872 )
                                 

Income before provision for income taxes

  $ 33,552     $ (8,449 )   $ 130,045     $ 155,148  

 

16

 

Variance

                               
   

Chemical

   

Electronics

   

Engineering

   

Total

 

Revenue

  $ (213,102 )   $ (501,369 )   $ (117,050 )   $ (831,521 )

Cost of Sales

    10,116       (289,718 )     11,936       (267,666 )

Gross Profit

    (223,218 )     (211,651 )     (128,986 )     (563,855 )

Gross Profit Percentage

    -15 %     -1 %     -14 %     -8 %
                                 

Operating Expenses

    76,063       (4,346 )     (3,719 )     67,998  

Operating Income (Loss)

    (299,281 )     (207,305 )     (125,267 )     (631,853 )

Other income (expenses)

    4,068       5,726       1,530       11,324  
                                 

Income (loss) before benefit from income taxes

  $ (295,213 )   $ (201,579 )   $ (123,737 )   $ (620,529 )

 

Revenues for the three months ended December 31, 2023 decreased by $286,666. The decrease is a result of decreased sales of $108,358 in the Engineering segment, $61,861 in the Electronics segment and $116,447 in the Chemical segment.

 

Gross profit for the three months ended December 31, 2023 decreased by $154,057. The decrease in gross profit resulted primarily from decreased sales in all segments.

 

Revenues for the nine months ended December 31, 2023 decreased by $831,521. The decrease is a result of decreased sales of $213,102 in the Chemical segment, $501,369 in the Electronics segment and $117,050 in the Engineering segment.

 

Gross profit for the nine months ended December 31, 2023 decreased by $563,855. The decrease in gross profit resulted primarily from decreased sales in all segments.

 

We are highly dependent upon certain customers. During the three months ended December 31, 2023, two customers accounted for 53% of our net revenue. Net revenues from foreign customers for the three months ended December 31, 2023 was $40,029 or 6%.

 

Revenues for the three months ended December 31, 2022 increased by $233,508. The increase is a result of increased sales of $95,899 in the Engineering segment, $137,543 in the Electronics segment and $66 in the Chemical segment.

 

Gross profit for the three months ended December 31, 2022 increased by $149,365. The increase in gross profit resulted primarily from increased sales in Electronics and Engineering sales.

 

Revenues for the nine months ended December 31, 2022 increased by $721,967. The increase is a result of increased sales of $31,553 in the Chemical segment, $672,434 in the Electronics segment and $17,980 in the Engineering segment.

 

Gross profit for the nine months ended December 31, 2022 increased by $425,811. The increase in gross profit resulted primarily from increased sales in Electronics and Chemical sales.

 

We are highly dependent upon certain customers. During the three months ended December 31, 2022, two customers accounted for 50% of our net revenue. Net revenues from foreign customers for the three months ended December 31, 2022 was $80,465 or 8%.

 

Loss from operations for the three months ended December 31, 2023 was $105,387 compared to income from operations for the three months ended December 31, 2022 of $92,753.

 

Other income decreased $827 for the three months ended December 31, 2023.

 

Other income increased $11,324 for the nine months ended December 31, 2023. The increase is mainly attributable reduced interest and finance costs.

 

The foregoing resulted in net loss before provision for income taxes for the three and nine months ended December 31, 2023 of $(105,015) and $(465,381) respectively. Earnings per share were $(0.00) and $(0.01) for the three and nine months ended December 31, 2023, respectively.

 

17

 

LIQUIDITY AND CAPITAL RESOURCES  

 

At December 31, 2023, we had cash and cash equivalents of $661,985 as compared to $1,003,730 at March 31, 2023. The $341,745 decrease was primarily the result of cash used in operations during the nine-month period in the amount of $495,138, cash used in investing activities in the amount of $14,515 offset by cash provided in financing activities of $167,908. Our cash will continue to be used for increased marketing costs, and increased production labor costs all in an attempt to increase our revenue, as well as increased expenditures for our internal R&D.  We expect to have enough cash to fund operations for the next twelve months.    

 

Below is a summary of our cash flow for the nine-month ending periods indicated:

 

   

December 31, 2023

   

December 31, 2022

 

Net cash provided by (used in) operating activities

  $ (495,137 )   $ 215,022  

Net cash provided by (used in) investing activities

    (14,515 )     -  

Cash flows provided (used) in financing activities:

    167,907       (255,835 )

Net increase (decrease) in cash and cash equivalents

  $ (341,745 )   $ (40,813 )

Cash and cash equivalents - beginning of period

  $ 1,003,730     $ 1,038,498  

Cash and cash equivalents - end of period

  $ 661,985     $ 997,685  

 

Future Sources of Liquidity:

 

We expect that growth with profitable customers and continued focus on new customers will enable us to generate cash flows from operating activities during fiscal 2024.

 

Based on current expectations, we believe that our existing cash and cash equivalents of $661,985 as of December 31, 2023, and other potential sources of cash will be sufficient to meet our cash requirements. Our ability to meet these requirements will depend on our ability to generate cash in the future, which is subject to general economic, financial, competitive, legislative, regulatory and other factors that are beyond our control.

 

OPERATING ACTIVITIES 

 

Net cash used by operating activities was $(495,137) for the nine months ended December 31, 2023, as compared to net cash provided by operating activities of $215,022 for the nine months ended December 31, 2022. The cash used during the nine months ended December 31, 2023 was primarily due to a net loss of $465,381, an increase in net operating assets of $144,104, offset by a decrease in net operating liabilities of $197,273, write-off of inventories of $33,945, depreciation and amortization of $3,370, and stock based compensation of $3,096 (see Note 11 Warrant Liability), and non-cash interest expense of $17,167.

 

INVESTING ACTIVITIES

 

Cash used in investing activities for the nine months ended December 31, 2023 was $14,515 for the purchase of an intangible asset.

 

FINANCING ACTIVITIES

 

For the nine months ended December 31, 2023, net cash provided by financing activities was $167,907 due to a net borrowing and payments in the line of credit of $185,569, a decrease in due to stockholder of $13,626 and repayments on the PPP loan of $4,035.

 

18

 

OFF BALANCE SHEET ARRANGEMENTS

 

We have no off-balance sheet arrangements that have had or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

Concentration of Credit Risk

 

Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable.

 

Cash and cash equivalents – For financial statement purposes, the Company considers as cash equivalents all highly liquid investments with an original maturity of three months or less at inception. The Company deposits cash and cash equivalents with high credit quality financial institutions and believes that any amounts in excess of insurance limitations to be at minimal risk. Cash and cash equivalents held at these accounts are currently insured by the Federal Deposit Insurance Corporation (“FDIC”) up to a maximum of $250,000. At December 31, 2023, approximately $412,000 exceeded the FDIC limit.

 

Our sales are materially dependent on a small group of customers, as noted in Note 6 of our condensed consolidated financial statements. We monitor our credit risk associated with our receivables on a routine basis. We also maintain credit controls for evaluating and granting customer credit. 

 

ITEM 4. CONTROLS AND PROCEDURES

 

EVALUATION OF DISCLOSURE CONTROLS AND PROCEDURES

 

The Company's management, including the Company's principal executive officer and principal financial officer, have evaluated the effectiveness of the Company's "disclosure controls and procedures," as such term is defined in Ru1e 13a-15(e) promulgated under the Securities Exchange Act of 1934, as amended, (the "Exchange Act"). Based upon their evaluation, the principal executive officer and principal financial officer concluded that, as of the end of the period covered by this report, the Company's disclosure controls and procedures were not effective for the purpose of ensuring that the information required to be disclosed in the reports that the Company files or submits under the Exchange Act with the Securities and Exchange Commission (the "SEC") (1) is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms, and (2) is accumulated and communicated to the Company's management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. During the quarterly and year to date period ended December 31, 2022, there were no changes in the Company's internal control over financial reporting which materially affected, or are reasonably likely to materially affect, the Company's internal controls over financial reporting. 

 

The determination that our disclosure controls and procedures were not effective as of December 31, 2023, is a result of:

 

a. Deficiencies in Internal Control Structure Environment. During the current year, the Company’s focus was on expanding their customer base to initiate revenue production.  

 

b. Inadequate staffing and supervision within the accounting operations of our company. The relatively small number of employees who are responsible for accounting functions prevents the Company from segregating duties within its internal control system. The inadequate segregation of duties is a weakness because it could lead to the untimely identification and resolution of accounting and disclosure matters or could lead to a failure to perform timely and effective reviews.  The Company’s plan is to expand its accounting operations as the business of the Company expands. 

 

The Company believes that the financial statements present fairly, in all material respects, the Company’s condensed consolidated balance sheets as of December 31, 2023, and March 31, 2023 and the related condensed consolidated statements of operations, and cash flows for the three and nine months ended December 31, 2023 and 2022, in conformity with generally accepted accounting principles, notwithstanding the material weaknesses we identified. 

 

CHANGES IN INTERNAL CONTROLS OVER FINANCIAL REPORTING

 

There were no changes in our internal control over financial reporting that occurred during our last fiscal quarter to which this report relates that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

19

 

PART II. OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS

 

None

 

ITEM 1A. RISK FACTORS

 

There have been no material changes to the risk factors contained in our Annual Report on Form 10-K for the year ended March 31, 2022. 

 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

 

None

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

 

None 

 

ITEM 4. MINE SAFETY DISCLOSURES

 

None

 

ITEM 5. OTHER INFORMATION

 

None 

 

ITEM 6. EXHIBITS.

 

(a) Exhibit No.

 

21.1

Subsidiaries of the Company

   

31.1

Certification of Chief Executive Officer and Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 

32.1

Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

101.INS**

Inline XBRL Instance

101.SCH**

Inline XBRL Taxonomy Extension Schema

101.CAL**

Inline XBRL Taxonomy Extension Calculation

101.DEF**

Inline XBRL Taxonomy Extension Definition

101.LAB**

Inline XBRL Taxonomy Extension Labels

101.PRE**

Inline XBRL Taxonomy Extension Presentation

104

Cover Page Interactive Data File (embedded within the Inline XBRL and contained in Exhibit 101)

 

** XBRL information is furnished and not filed or a part of a registration statement or prospectus for purposes of sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of section 18 of the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections.

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

ADM TRONICS UNLIMITED, INC.

 
 

(Registrant)

 
       
       
 

By:

/s/ Andre' DiMino

 
   

Andre' DiMino, Chief Executive

 
   

Officer and Chief Financial

Officer

 

 

Dated:

Northvale, New Jersey

 

February 20, 2024

 

20